Sofía Braga
YOU?
Author Swipe
View article: Cervical cancer classification from Pap smear cells using machine learning models
Cervical cancer classification from Pap smear cells using machine learning models Open
Cervical cancer is one of the most common cancers among women worldwide, and early diagnosis is essential to reduce mortality. This study investigated the use of machine learning techniques to classify normal and abnormal cervical cells us…
View article: Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial
Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial Open
T-DXd demonstrated promising intracranial activity in pretreated HER2-low ABC patients with active BMs. Further studies are needed to validate these results in larger cohorts. This trial is registered with ClinicalTrials.gov, NCT04420598.
View article: OCTS-03 A MULTICENTER, OPEN-LABEL, SINGLE-ARM, MULTICOHORT PHASE II CLINICAL TRIAL OF TRASTUZUMAB DERUXTECAN IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE AND HER2-LOW ADVANCED BREAST CANCER (ABC) WITH BRAIN METASTASES AND/OR LEPTOMENINGEAL CARCINOMATOSIS (LMC) – THE DEBBRAH STUDY
OCTS-03 A MULTICENTER, OPEN-LABEL, SINGLE-ARM, MULTICOHORT PHASE II CLINICAL TRIAL OF TRASTUZUMAB DERUXTECAN IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE AND HER2-LOW ADVANCED BREAST CANCER (ABC) WITH BRAIN METASTASES AND/OR LEPTOMENINGEAL CARCINOMATOSIS (LMC) – THE DEBBRAH STUDY Open
The DEBBRAH study (NCT04420598) evaluated the efficacy and safety of trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate, in patients with HER2-positive and HER2-low ABC with brain metastases (BM) and/or LMC. Forty-one patients aged…
View article: Preclinical and clinical evaluation through serial colonoscopic evaluation of neratinib‐induced diarrhea in <scp>HER2</scp>‐positive breast cancer—A pilot study
Preclinical and clinical evaluation through serial colonoscopic evaluation of neratinib‐induced diarrhea in <span>HER2</span>‐positive breast cancer—A pilot study Open
The irreversible pan‐HER tyrosine kinase inhibitor neratinib is approved for patients with HER2‐positive, early‐stage and metastatic breast cancer (BC). Neratinib‐associated diarrhea is the most common reason for early discontinuation. Pre…
View article: Optimal [<sup>18</sup>F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
Optimal [<sup>18</sup>F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial Open
The PHERGain trial investigated the potential of metabolic imaging to identify candidates for chemotherapy deescalation in human epidermal growth factor receptor 2 (HER2)-positive, invasive, operable breast cancer with at least 1 breast le…
View article: Adipocyte Microenvironment in Ovarian Cancer: A Critical Contributor?
Adipocyte Microenvironment in Ovarian Cancer: A Critical Contributor? Open
Ovarian cancer is one of the most common gynecological malignancies and has low survival rates. One of the main determinants of this unfavorable prognosis is the high rate of peritoneal metastasis at diagnosis, closely related to its morbi…
View article: 237P Real-world safety and efficacy of trastuzumab-deruxtecan (T-DXd) in HER2-positive advanced breast cancer (ABC) elderly patients (pts): The TREX-Old retrospective registry
237P Real-world safety and efficacy of trastuzumab-deruxtecan (T-DXd) in HER2-positive advanced breast cancer (ABC) elderly patients (pts): The TREX-Old retrospective registry Open
One third of ABC pts is currently represented by women aged over 70. However, this population remains under-represented in clinical trials. Recently, T-DXd revolutionized the treatment of HER2 positive ABC, demonstrating its efficacy in DE…
View article: Sialyl LewisX/A and Cytokeratin Crosstalk in Triple Negative Breast Cancer
Sialyl LewisX/A and Cytokeratin Crosstalk in Triple Negative Breast Cancer Open
Triple-negative breast cancer (TNBC) encompasses multiple entities and is generally highly aggressive and metastatic. We aimed to determine the clinical and biological relevance of Sialyl-Lewis X and A (sLeX/A)—a fucosylated glycan involve…
View article: Association of Tumor-Infiltrating Lymphocytes With Survival in Stages II and III Colorectal Cancer
Association of Tumor-Infiltrating Lymphocytes With Survival in Stages II and III Colorectal Cancer Open
[This corrects the article DOI: 10.7759/cureus.31144.].
View article: Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group
Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer—results from an international, multicenter analysis coordinated by the AGMT Study Group Open
In this large international dataset of metastatic TNBC, the frequency of HER2-low was 32.0%. Neither in univariable nor in multivariable analysis HER2-low showed any influence on OS.
View article: Trastuzumab and Pertuzumab without Chemotherapy in Early-Stage HER2+ Breast Cancer: a Plain Language Summary of the PHERGain Study
Trastuzumab and Pertuzumab without Chemotherapy in Early-Stage HER2+ Breast Cancer: a Plain Language Summary of the PHERGain Study Open
Early monitoring of how well participants respond to treatment by FDG-PET scan seems to identify participants with operable HER2-positive breast cancer who were more likely to benefit from trastuzumab and pertuzumab without the need to hav…
View article: Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial Open
Background Trastuzumab deruxtecan (T-DXd) has shown durable antitumor activity in pretreated patients with HER2-positive advanced breast cancer (ABC), but its efficacy has not yet been evaluated in patients with active brain metastases (BM…
View article: Human Microbiota and Immunotherapy in Breast Cancer - A Review of Recent Developments
Human Microbiota and Immunotherapy in Breast Cancer - A Review of Recent Developments Open
Breast cancer (BC) is the most common malignancy and the second cause of cancer-specific death in women from high-income countries. Infectious agents are the third most important risk factor for cancer incidence after tobacco and obesity. …
View article: Refining Therapy in Patients with HER2-Positive Breast Cancer with Central Nervous System Metastasis
Refining Therapy in Patients with HER2-Positive Breast Cancer with Central Nervous System Metastasis Open
Background: Brain metastasis (BM) is a major clinical problem in metastatic breast cancer (MBC), occurring in 50% of patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Historically omitted from clinical …
View article: Review of neoadjuvant chemotherapy characteristics in advanced epithelial ovarian cancer: experience from two cancer centers
Review of neoadjuvant chemotherapy characteristics in advanced epithelial ovarian cancer: experience from two cancer centers Open
Background: This study aimed to review the characteristics and survival of patients with Advanced Epithelial Ovarian Cancer undergoing neoadjuvant chemotherapy (NACT) and the impact of timing of surgery and post-operative adjuvant chemothe…
View article: Circulating low density neutrophils of breast cancer patients are associated with their worse prognosis due to the impairment of T cell responses
Circulating low density neutrophils of breast cancer patients are associated with their worse prognosis due to the impairment of T cell responses Open
Neutrophils are prominent immune components of tumors, having either anti-tumor (N1) or pro-tumor activity (N2). Circulating neutrophils, divided into high density neutrophils (HDN) and low density neutrophils (LDN), functionally mirror th…
View article: Next-Generation Sequencing in Breast Cancer Management: A Case Report of Genomic Tumour Evolution over Time
Next-Generation Sequencing in Breast Cancer Management: A Case Report of Genomic Tumour Evolution over Time Open
The clinicopathological breast cancer subtypes are used in clinical practice to better anticipate biological behaviour and guide systemic treatment strategy. In the adjuvant setting, genomic assay recurrence scores became widely available …